ID   LNCAP-AAR
AC   CVCL_ZX07
DR   cancercelllines; CVCL_ZX07
DR   Wikidata; Q102114473
RX   CelloPub=CLPUB00570;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:68639; Abiraterone acetate.
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1379 ! LNCaP clone FGC
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 7
//
RX   CelloPub=CLPUB00570;
RA   da Luz Efe F.;
RT   "Establishment and characterization of abiraterone acetate resistant
RT   prostate cancer cell line.";
RL   Thesis BSc (2019), Universidade Federal de Santa Catarina, Brazil.
//